AMP-Activated Protein Kinase Suppresses the In Vitro and In Vivo Proliferation of Hepatocellular Carcinoma

Jidong Cheng1*, Tianliang Huang1, Youfeng Li1, Yubai Guo2, Yuzhang Zhu1, Qingjia Wang1, Xiaojun Tan1, Weisheng Chen1, Yongneng Zhang1, Weijie Cheng1, Tetsuya Yamamoto3, Xubin Jing1*, Jiexiong Huang2*

1 Department of Internal Medicine, The First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, China, 2 Department of Pathology, The First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, China, 3 Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan

Abstract

AMP-activated protein kinase (AMPK) is a central metabolic sensor and plays an important role in regulating glucose, lipid and cholesterol metabolism. Therefore, AMPK is a key therapeutic target in diabetes. Recent pilot studies have suggested that diabetes drugs may reduce the risk of cancer by affecting the AMPK pathway. However, the association between AMPK and the proliferation of hepatocellular carcinoma (HCC) is unknown. In this study, we investigated the relationship between AMPK activity and the proliferation of HCC in cell lines, nude mice and human clinic samples. We first investigated the relationship between AMPK activity and cell proliferation in two HCC cell lines, PLC/PRF/5 and HepG2, by two AMPK activators, 5-aminoimidazole-4-carboxamide-1-h-D-ribofuranoside (AICAR) and metformin. AICAR and metformin treatment significantly inhibited the proliferation of HCC cells and induced cell cycle arrest at G1-S checkpoint. We then observed that metformin abrogated the growth of HCC xenografts in nude mice. The clinical pathology of AMPK activity in HCC, including cell proliferation, differential grade, tumor size and microvessel density, was studied by using 30 clinical tissue samples. In HCC tissue samples, phosphorylated AMPK was expressed mainly in cytoplasm. AMPK activity decreased significantly in HCC in comparison with paracancerous liver tissues (P < 0.05). AMPK activity was negatively correlated with the level of Ki-67 (a marker of cell proliferation), differential degradation and tumor size (P < 0.05), but not with microvessel density, hemorrhage or necrosis in HCC. Our findings suggest that AMPK activity inhibits the proliferation of HCC and AMPK might be an effective target for prevention and treatment of HCC.

Citation: Cheng J, Huang T, Li Y, Guo Y, Zhu Y, et al. (2014) AMP-Activated Protein Kinase Suppresses the In Vitro and In Vivo Proliferation of Hepatocellular Carcinoma. PLoS ONE 9(4): e93256. doi:10.1371/journal.pone.0093256

Editor: Salvatore Papa, Institute of Hepatology - Birkbeck, University of London, United Kingdom

Received June 14, 2013; Accepted March 4, 2014; Published April 7, 2014

Copyright: © 2014 Cheng et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by grants from the National Natural Science Foundation of China (81070673 and 81172263), the Special Foundation of Guangdong Province College Talent Introduction (10027425), and the Natural Science Foundation of Guangdong province (10151503102000013 and 520111010050120). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

E-mail: chengjidong36@hotmail.com (JC); xbjjing@stu.edu.cn (XJ); hjxcyjhx@21cn.com (JH)

Introduction

AMP-activated protein kinase (AMPK) is highly conserved as a heterotrimer. It contains α1, α2, β1, β2, γ1, γ2 and γ3 subunits with different alternative splicing forms, which results in different combinations of the AMPK complex [1]. AMPK is a sensor of cellular energy status and a regulator of metabolism. It is inactive unless phosphorylated by upstream kinases at a specific threonine residue (Thr-172) within the kinase domain and is sensitive to cellular AMP/ATP ratio, whereby a high AMP or low ATP level activates AMPK, whereby a high AMP or low ATP level activates AMPK [2,3]. AMPK activation can inhibit anabolic processes such as protein, lipid, or glycogen synthesis by phosphorylating a number of substrates [4]. However, it can also activate catabolic processes such as fatty acid oxidation and glycolysis [5]. Studies have confirmed that AMPK is involved in breast cancer, prostate cancer and lung cancer [6–8]. Much of the evidence shows that AMPK might be a therapeutic target for cancer. However, the investigation of the relationship between AMPK and cancer is still in its infancy.

The association between AMPK with several tumor suppressors suggests that therapeutic manipulation of this pathway using established diabetes drugs warrants further investigation in patients with cancer [9]. Liver kinase B1 (LKB1), the upstream activator of AMPK, was previously described as a tumor suppressor gene related to epithelial neoplasia. Loss of function of LKB1 is associated with Peutz-Jeghers syndrome, which is characterized by multiple gastrointestinal polyps and significantly increased lifetime risk of various epithelial cancers, including HCC [10,11]. LKB1 is both a regulator of gluconeogenesis in hepatocytes and a tumor suppressor gene in epithelial tissues. Recently, LKB1 was found to have a major role in phosphorylating and activating AMPK. In addition, downstream tumor suppressors have been identified [12].

The liver is one of the most important organs associated with digestion, detoxification, production and storage, so the liver has a high metabolic rate, and therefore liver diseases including HCC are associated with metabolic disorders [13]. HCC is one of the leading causes of cancer deaths in the world. However, the exact molecular mechanisms of HCC and effective prevention and
treatment are still unclear [14]. To date, the association between AMPK and HCC is unknown. In this study, we investigated the association between AMPK activity and cell proliferation in HCC cell lines and clinical samples of HCC. Our findings suggest that AMPK is involved in cell proliferation in HCC and might be an effective target for prevention and treatment of HCC.

**Materials and Methods**

All animal experiments were approved by the Ethics Committee for Animal Experimentation of the Shantou University Medical College. We add written consents from patients or their family members in the last two weeks according to the protocol approved by Shantou University Medical College’s human research committee. Because many patients of HCC in this study had passed over, the written consents of these patients were obtained from their family members. Written informed consents was obtained from patients or their family members, and the study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki, as reflected in approval by Shantou University Medical College’s human research committee.

**Cell lines, cell culture and reagents**

The human hepatoma cell lines, PLC/PRF/5 and HepG2, were obtained from the American Type Culture Collection. Cells (2×10⁵ cells) were grown in RPMI1640 (ICN; Biomedicals Inc.) supplemented with 10% fetal calf serum, 100 units/ml penicillin, and 100 units/ml streptomycin (Invitrogen). LKB1 (the upstream activator of AMPK) absent cell line, Hela cells, was obtained from the American Type Culture Collection as a control. 5-aminoimidazole-4-carboxamide-1-h-D-ribofuranoside (AICAR) and 1, 1-dimethylbiguanide hydrochloride (metformin) were purchased from Sigma (St. Louis, MO). Compound C (AMPK Inhibitor) was purchased from Sigma (St. Louis, MO).

**In vivo tumor models**

BALB/c-nu mice were obtained from SLC (Guangzhou, China). PLC/PRF/5 cells (2×10⁵) were inoculated s.c. in 3-week old male nu/nu mice for 4 points at both flanks (X2). After 1 week, metformin was dissolved in PBS and administered with i.p. injections (30 Ag/g body weight). The control group received vehicle only phosphate buffer saline (PBS). Number and weight of tumors were measured after 7 weeks of treatment. All animal experiments were approved by the Ethics Committee for Animal Experimentation of the Shantou University Medical College.

**Human tissue samples**

Tissue samples of cancerous and paracancerous tissues were obtained from 30 patients with HCC undergoing curative hepatectomy (segmental or lobar resection) at the First Hospital Affiliated of Shantou University Medical College between 2005 and 2009. Samples were fixed in 10% neutral formalin and embedded in paraffin for histopathological and immunohistochemistry examination. Fresh samples were stored at −80°C for western blot analysis. Data on alpha fetoprotein (AFP), albumin, globulin, total bilirubin (TBil), alanine aminotransferase (ALT), aspartate aminotransferase (AST), γ-glutamyltranspeptidase (γ-GTP), aspartic acid (ASP), and platelets (PLTs) were obtained from patient hospital records. Tumor size (diameter) was obtained from surgical records. HCC differential grade was classified according to the world health organization classification [15]. Liver fibrosis and hepatitis activity stage were classified according to the New Inuyama Classification [16].

Informed oral consent was obtained from each patient, and the study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki, as reflected in approval by our institution’s human research committee.

**MTT**

Cell proliferation was assessed by the (4, 5-dimethylthiazol-2-yl)-2, diphenyltetrazolium bromide (MTT) method and cell count. Cells were seeded at 4000 cells/well in 96-well plates containing the test compounds for the indicated times and then incubated with 30 μL MTT solution (5 mg/mL in PBS) for 3 h at 37°C. Optical density was determined by an enzyme-linked immuno-sorbent assay (ELISA) reader.

**Flow cytometry**

For cell cycle analysis, cells were treated with or without AICAR or metformin for 1.5 days. Cells (1×10⁶) were trypsinized and fixed in 70% ethanol overnight. Fixed cells were filtered with propidium iodide (50 μg/mL) for 30 min at room temperature. Cells were filtered with use of a 5 mL polystyrene round-bottom tube with a cell-strainer cap prior to flow cytometry. Flow cytometry was performed with a FACSVantage SE cell sorter (Becton Dickinson). Cell cycle analysis was performed with the ModFit LT software.

**BrdU Incorporation Assay**

Cell proliferation was quantified by the measuring the BrdU incorporation during DNA synthesis with BrdU cell proliferation Detection Kit (KeyGen Biotech). The assay was performed according to the manufacturer's manual. In brief, equal number of PLC/PRF5 and HepG2 cells was plated in 24-well plates and serum-starved overnight. Cells were then treated with metformin (10 mM) for 24 minutes, followed by FBS replenishment and BrdU labeling for 1 hours. The BrdU labeling signal was quantified by PE-BrdU antibody and flow cytometry. Each assay was done in triplicate. The experiments were performed at least three times independently.

**RNA Interference**

AMPKz1 siRNA was obtained from Santa Cruz Biochemistry (sc-270142). A pool of 3 target-specific 19–25 nt siRNAs designed to knock down AMPKz1 gene expression. Cells were inoculated into the 24-mesh board at 37°C, 5% CO₂, and saturated humidity conditions up to the convergence rate arriving at 70%–80%. Transfection steps were according to the RNAi manual of Santa Cruz Biotechnology. The proliferation of control, metformin treatment group and siRNA plus metformin treatment group were compared. The proliferation of cancer cell lines was detected by cell count.

**Western blot analysis**

Cells and Liver tissues were sonicated in 100 μl RIPA buffer (1×PBS, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS, 100 μg/ml phenyl-methylsulfonyl fluoride, 45 μg/ml aprotinin, 1 mol sodium orthovanadate), homogenized, and centrifuged (10000 g for 10 min). The supernatant was used for protein determination by use of a BCA Protein Assay Kit (Pierce, IL, United States) and electrophoresis. Samples containing 30 μg proteins were added to SDS-PAGE loading buffer, heated for 5 min at 100°C, loaded onto a gel and then electrophoretically transferred onto polyvinylidene difluoride membrane. The membranes were immunoblotted with anti-phosphor-AMPK antibody (AMPK-p) (Cell signaling Technology, CA, United States), anti-
AMPK antibody (Cell signaling Technology, CA, United States), anti-P21CIP antibody (Maixin Bio, Fuzhou, China), anti-p27KIP antibody (Maixin Bio, Fuzhou, China) or anti-cyclin D1 antibody (Maixin Bio, Fuzhou, China), followed by the secondary antibody horseradish peroxidase-conjugated IgG (Vector Laboratories, Burlingame, CA, United States). Signals were developed by chemiluminescence using an enhanced chemiluminescence kit (Amersham, Piscataway, United States). Loading controls of western blot were performed by anti-β-actin antibody.

Immunohistochemistry

Tissue sections (5-µm thick) were deparaffinized with xylene. After dehydration in absolute ethanol 3 times for 3 min each, sections were incubated in 3% (v/v) hydrogen peroxide for 10 min at room temperature, and then washed 3 times for 3 min each in phosphate-buffered saline (PBS; pH 7.4). Tissue sections were microwaved for 20 min in 10 mM citrate buffer (pH 6.0) and washed 3 times in PBS for 5 min each. The paired sections were blocked for 10 min in PBS containing 5% normal serum (1:50–200 dilution) and then incubated with goat anti-phosphor-AMPK (Cell Signaling Technology), mouse anti-Ki-67 or mouse anti-CD34 (Maixin_bio) at 4°C overnight. Sections were washed twice in PBS and incubated with biotinylated secondary antibody (1:100) (Vector Laboratories, Burlingame, CA, United States). The color reaction was performed by DAB and counterstaining was done by hematoxylin & eosin. The negative control was performed by omitting the primary antibody.

Semi-quantitative analysis of AMPK activity

The degree of staining was categorized by the extent and intensity of the staining. Three independent observers screened all sections as a semiquantitative evaluation of immunostaining. The immunoreactive score was determined by the sum of the extent and intensity of staining as reported previously [17]. The intensity of staining was scored on a scale of 0 to 3 (0 = negative staining, 1 = weakly positive staining, 2 = moderately positive staining, and 3 = strongly positive staining). The extent of staining (“extent of distribution” of positive cells) was estimated on a scale of 0 to 3 (0 = negative, 1 = positive staining in 1–30% of cells, 2 = positive staining in 30–70%; 3 = positive staining in 70–100%), for a final staining score = (extent score+intensity score)/2.
Quantization of growth index and microvessel density (MVD)

The percentage of Ki-67-positive cells was calculated as the growth index of HCC. The images of Ki-67 immunostaining by DAB were scanned with use of an Olympus CCD camera and analyzed by Image J (National Institute of Health). The growth index of HCC was calculated as follows: HCC = Ki-67 positive cell number/total cell number in a field. The mean of 5 low-power fields was used.

Figure 2. Metformin abrogated the growth of HCC xenografts in nude mice. PLC/PRF/5 cancer cells (2×10^6) were inoculated s.c. in 5-week old male nu/nu mice at both flanks for 4 points. After 1 week, metformin was dissolved in PBS and given i.p. (30 Ag/g body weight). The control group received PBS only. Control and metformin-treated groups were treated for 7 weeks. (A): Representative picture for tumorigenesis number and size in control and metformin treatment nu/nu mice. (B): The tumorigenesis percentage. (C): Average tumor weight. (D): Western blot analysis of phosphor-AMPK (AMPK-p) and AMPK in control and metformin treated groups. (E): The expression of Ki-67 in control and metformin-treated groups by immunohistochemistry. Data are mean±SD. *p<0.05.

doi:10.1371/journal.pone.0093256.g002

Figure 3. Immunohistochemistry of phosphor-AMPK showed a lower degree of AMPK activity in HCC tissues than in paracancerous liver tissues. (A) Positive signals were detected in cytoplasm and occasionally in nucleus. (B) Negative control (omitting primary antibody). (C)Representative images of three samples of HCC and paracancerous liver tissue showing AMPK activity. (D) Relative AMPK activity in 30 tissue samples. Data are mean±SD. *p<0.05 (E) Western blot analysis of phosphor-AMPK (AMPK-p) and AMPK. Representative bands from five independent experiments.

doi:10.1371/journal.pone.0093256.g003
We assessed MVD as a percentage of the endothelial area as follows: MVD = CD31-positive area/total field area. The images were scanned and analyzed by use of Image J. The mean of 5 low-power fields was used.

Statistical analysis

Statistical significance was determined by the Kruskal–Wallis test and Kendall rank correlation test (non-parameter statistical methods). The significance level was set at $P < 0.05$.

Results

AMPK activating agents inhibit cell growth and arrest cell cycle in HCC cell lines. To investigate the relationship between AMPK activity and cell proliferation, we used HCC cell lines, PLC/PRF/5 and HepG2, to study the effect of the AMPK-activating agents, AICAR and metformin. Western blot analysis revealed that AMPK could be activated by both AICAR and metformin (Fig. 1A). MTT results indicated that both AICAR and metformin inhibited cell proliferation in a time- and dose-dependent manner (Fig. 1B and C). BrdU incorporation was significant decreased in both of PLC/PRF/5 and HepG2 cells by metformin treatment for 24 hours (Fig. 1D), to imply that DNA synthesis was inhibited. The cell growth inhibition was also further confirmed by cell count method. In addition, the role of AMPK pathway was investigated by silencing AMPK using AMPKα1 siRNA and the pharmacological AMPK inhibitor compound C treatment (Fig. 1E). The growth inhibition of metformin was rescued by AMPKα1 siRNA and compound C treatment. As a control, Hela cells, a LKB1 (the upstream activator of AMPK) absent cell line, did not show cell growth inhibition by AICAR and metformin treatment (Fig. 1F).

We further investigated the mechanism of AICAR and metformin affecting cell proliferation by flow cytometry. Activation of AMPK by AICAR or metformin induced G1 cell cycle arrest in PLC/PRF5 and HepG2 cells. Representative DNA histograms for PLC/PRF5 cells are shown in Figure 1G, which

Figure 4. The correlation between AMPK activity and cell proliferation of HCC. (A) The growth index of HCC was represented by the expression of Ki-67. (B) Significant negative correlation between AMPK activity and growth index in HCC ($r = -0.41$, $p<0.05$).

doi:10.1371/journal.pone.0093256.g004

Figure 5. AMPK activity in different degrees of tumor grade in HCC. Data are mean ± SD. $P<0.05$.

doi:10.1371/journal.pone.0093256.g005

Figure 6. Correlation between AMPK activity and tumor size in HCC ($p<0.05$).

doi:10.1371/journal.pone.0093256.g006
The inhibition of cell proliferation by AMPK. No obvious sub-G0 (apoptosis) peak was observed.

The expressions of cell cycle G1-S checkpoint regulatory proteins, including p21<sup>CIP</sup>, p27<sup>KIP</sup> and cyclin D1, were further studied by western blot. P21<sup>CIP</sup> and p27<sup>KIP</sup> expressions were up-regulated and cyclin D1 expression was inhibited after AICAR and metformin treatment for 24 hours (Fig. 1H). The results suggested that AMPK activity inhibits G1-S checkpoint and induces cell cycle arrest in HCC cells.

Metformin attenuated the growth of cancer cells in nude mice

We examined the effects of metformin on the growth of cancer cells in vivo. Immunodeficient nude mice were inoculated with PLC/PRF5 cancer cells (s.c.). After the growth of tumors, mice underwent metformin treatment (i.p.). The percentage of tumorigenesis and the average tumor weight of the metformin-treated group were significantly reduced in comparison with that of the vehicle-treated control group (Fig. 2A, 2B, 2C). AMPK activity was up-regulated by metformin treatment (Fig. 2D); whereas, the expression of Ki-67 was decreased by metformin treatment in tumor tissue (Figure 2E). There were no significant differences in body weight and serum glucose level between the control and metformin-treated groups (data not shown).

AMPK activity in HCC and paracancerous liver tissues

We investigated AMPK activity in 30 samples of HCC and paracancerous liver tissues by immunohistochemistry and western blot analysis. Immunostaining for AMPK-p was observed in 90% (27/30) of HCC tissues and 93.3% (28/30) of paracancerous liver tissues, mainly in cytoplasm but occasionally in nucleus (Fig. 3A). No positive signal was detected in the negative controls (Fig. 3B). AMPK-p staining was detected in both HCC and paracancerous liver tissues, with weaker staining in HCC tissues (Fig. 3C, 3D). Western blot analysis revealed the level of AMPK activity was significantly lower in HCC than paracancerous tissues (Fig. 3E).

Correlation of AMPK activity and cell proliferation in HCC

The growth index of HCC was determined by the expression of Ki-67. AMPK activity was negatively correlated with the expression of Ki-67 in HCC (r = -0.41, p < 0.05) (Fig. 4).

Correlation of AMPK activity and tumor differential grade in HCC

AMPK activity showed a significant down regulation with decreasing differential grade (P < 0.05) (Fig. 5).

Correlation of AMPK activity and tumor size in HCC

AMPK activity was negatively correlated with tumor size (diameter) (r = -0.394, p < 0.05) (Fig. 6), suggesting that AMPK activity inhibits the proliferation of HCC.

Correlation between AMPK activity and MVD in HCC

HCC is a hypervascular tumor. Angiogenesis is a prerequisite for development and growth in HCC. To study the correlation between angiogenesis and AMPK activity, we analyzed CD34

| Table 1. The correlation between AMPK-p and hemorrhage and/or necrosis in HCC. |
| Groups | (+/-) | N | AMPK-p relative value | p value |
|--------|-------|---|-----------------------|---------|
| Hemorrhage | (+) | 6 | 0.9±0.4 | 0.860 |
| | (-) | 24 | 0.9±0.7 | |
| Necrosis | (+) | 12 | 1.2±0.7 | 0.151 |
| | (-) | 18 | 0.8±0.5 | |
| Hemorrhage or Necrosis | (+) | 15 | 1.1±0.7 | 0.134 |
| | (-) | 15 | 0.7±0.6 | |

AMPK: AMP-activated protein kinase. HCC: hepatocellular carcinoma.
doi:10.1371/journal.pone.0093256.t001
immunostaining (Fig. 7A) to measure MVD. We found no significant correlation between AMPK activity and MVD ($r = 0.056, p > 0.05$) (Fig. 7B).

Correlation between AMPK activity and hemorrhage and/or necrosis

As a hypervascular tumor, hemorrhage and necrosis are impartment pathological characters in HCC. However, we found no correlation between AMPK activity and hemorrhage and/or necrosis in HCC tissues (Table 1).

Correlation between clinical features and activation of AMPK

The correlation between AMPK activity and clinical data, including the levels of AFP, albumin, globulin, TBil, ALT, AST, $\gamma$-GTP, ASP, and PLTs, are shown in Table 2. A significant correlation was only observed between AMPK activity and globulin level ($p < 0.05$). To investigate whether liver fibrosis and hepatitis activity affect AMPK activity in paracancerous tissues, we compared AMPK activity in different liver fibrosis and hepatitis activity grades in paracancerous tissues. We found no correlation between the degree of liver fibrosis and hepatitis activity with AMPK (Fig. 8A, 8B).

Discussion

In this study, we investigated the relationship between AMPK activity and HCC proliferation in cell lines, animal model and clinical samples. In *in vitro* study two AMPK activators, AICAR and metformin, inhibited the proliferation and induced cell cycle arrest in the HCC cell lines, PLC/PRF/5 and HepG2. In *in vivo* study metformin attenuated the growth of cancer cells in nude mice. Furthermore, in clinical HCC tissue samples, we found lower AMPK activity in HCC than in paracancerous liver tissues. AMPK activity was negatively correlated with cell growth, tumor

Table 2. The correlation between AMPK-p and the clinical features of HCC patients.

| Clinical Feature | n  | rs value | P value |
|------------------|----|----------|---------|
| Age              | 30 | 0.32     | 0.088   |
| AFP              | 23 | −0.36    | 0.093   |
| Albumin          | 28 | −0.24    | 0.220   |
| Globulin         | 28 | −0.4     | 0.030*  |
| TBIL             | 28 | 0.21     | 0.286   |
| ALT              | 28 | 0.01     | 0.972   |
| AST              | 28 | −0.21    | 0.293   |
| $\gamma$-GTP     | 28 | −0.24    | 0.226   |
| ALP              | 28 | 0.14     | 0.489   |
| PLT              | 28 | −0.10    | 0.598   |

*P < 0.05.

AMPK: AMP-activated protein kinase. HCC: hepatocellular carcinoma. AFP: alpha fetoprotein. TBil: total bilirubin. ALT: alanine aminotransferase. AST: aspartate aminotransferase. $\gamma$-GTP: $\gamma$-glutamyltranspeptidase. ALP: alkaline phosphatase. PLT: platelet.

doi:10.1371/journal.pone.0093256.t002
AMPK is a heterotrimeric complex composed of a catalytic α subunit and regulatory β and γ subunits, each of which is encoded by 2 or 3 distinct genes [18]. AMPK is activated by increases in AMP/ATP ratio caused by cellular and environmental stress, such as hypoxia, ischemia and heat shock [19]. Studies have shown that AMPK regulates the metabolism of fatty acids and glycogen, protein synthesis and cell proliferation. AMPK regulates multiple metabolic pathways through direct phosphorylation of substrates [20]. The proper regulation of AMPK is highly relevant to metabolic disorders such as obesity and diabetes, in which AMPK functions at multiple steps. As a sensor of cellular energy status and a regulator of metabolism, AMPK regulates multiple metabolic processes inside the cell and can be considered as a potential candidate for the metabolic switch from normal to malignant growth [21,22]. Malignant tumors, including HCC, represent a fundamental metabolic difference between cancer and normal cells. Cancer cells use glucose at a higher rate than do normal cells and metabolize glucose mainly to lactate rather than through mitochondrial oxidative phosphorylation to produce ATP under normal oxygen levels, even though the ATP productivity rate is much lower [23]. Elevated cellular AMP level activates AMPK to inhibit ATP-consuming anabolic pathways and activate ATP-generating catabolic pathways to maintain cellular energy homeostasis [24]. Recent studies show that metformin, an AMPK activator, inhibits HCC cell growth in vitro by inducing cell cycle arrest and decreases the risk of HCC in the general population [25,26]. In this study, we found a lower AMPK activity in HCC than in paracancerous liver tissues, suggesting that the loss of AMPK activity is an important event in the development of HCC. We found that AMPK activity was related to cell growth and differentiation in HCC cell lines and clinical samples, suggesting that AMPK is an important regulator of HCC proliferation and differentiation, through its mechanism in cellular energy homeostasis in HCC needs further study.

Having determined that tumor progression is inversely related to AMPK activity, we tested whether pharmacological activators of AMPK could suppress HCC. MTT, cell count and flow cytometry indicated that AICAR and metformin inhibited cell growth, which suggests that AMPK plays a significant role in the regulation of cell proliferation in HCC cells. In HCC cells, AICAR and metformin treatment might activate AMPK via an LKB1–AMPK pathway, thus resulting in activation of some or even all of the downstream pathways for proliferation-inhibitory and anti-tumor effects [27]. These results provide solid evidence that AMPK activators can delay the growth of HCC. Metformin has been in clinical treatment for type 2 diabetes for many years and is well tolerated, so it could be tested immediately in cancer patients.

Of note, LKB1 is a well-recognized tumor suppressor, and mutations in the gene encoding LKB1 cause the rare inherited Peutz-Jeghers syndrome. The LKB1-AMPK pathway may function as a cellular energy-sensing checkpoint that controls cell growth and proliferation according to the availability of fuel supplies [28]. The tumor-suppressor LKB1 is upstream of AMPK, and its activity might have a suppressive effect on HCC. Our findings suggest that AMPK activity is negatively correlated with cell growth and induces growth inhibition in HCC. AMPK could be a therapeutic target for HCC.

AMPK activation by AICAR has also been recently reported to inhibit proliferation of various cancer cell lines in vitro and in vivo by increasing p21cip1, p27kip1 and p53 [32–34]. The S phase cell reduction may be an important event in cell cycle arrest induced in HCC cell lines by AMPK activators. Future studies need to address how AMPK activator inhibits HCC cells in crossing the G1/S boundary.

Angiogenesis is a prerequisite for development and growth of different human tumors. For HCC, only a few studies have described the mechanisms of microvessel formation [35]. No report has described the relationship between angiogenesis and AMPK activity in HCC. In both experimental and clinical studies, AMPK induces angiogenesis. In this study, we did not find AMPK activity correlated with MVD in HCC tissues. However, our results are limited in showing the correlation of AMPK activity in HCC cells and angiogenesis, and the relationship between AMPK activity in microvessels of HCC and angiogenesis needs further study.

We found no significant correlation between AMPK activity and hemorrhage and/or necrosis, or between AMPK activity and clinical features, including levels of AFP, albumin, TBil, ALT, AST, r-GTP, ASP, or PLT, except for globulin. In addition, we found no effect of AMPK activity on degrees of liver fibrosis and hepatitis activity in paracancerous liver tissues. Therefore, AMPK activity could be independent of other clinical pathological features during the development of HCC.

In this study, we demonstrate for the first time in cell lines and HCC tissue samples that AMPK and AMPK-activating drugs traditionally used to counter the metabolic changes observed in diabetes could be effective in restraining HCC cell proliferation. AMPK might inhibit HCC by regulating metabolism and the cell cycle, so the AMPK system might be a great therapeutic option for HCC.

**Acknowledgments**

We express our thanks to the members of the Department of Pathology for their technical support. The experiments were mainly carried out in the Central Laboratory, First Affiliated Hospital, Shantou University Medical College.

**Author Contributions**

Conceived and designed the experiments: JC XJ JH. Performed the experiments: TH Y. Zhu W. Chen YG QW XTYL Y. Zhang W. Cheng. Analyzed the data: JC TY. Contributed reagents/materials/analysis tools: JC XJ JH. Wrote the paper: JC.

**References**

1. Hardie DG (2007) AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat Rev Mol Cell Biol 8: 774–785.

2. Hardie DG, Hawley SA, Scott JW (2006) AMP-activated protein kinase–development of the energy sensor concept. J Physiol 574: 7–15.
AMPK Suppresses the Proliferation of HCC

3. Tamao P, Hawley SA, Clarke RG, Mustard KJ, Green K, et al. (2006) Regulation of the energy sensor AMP-activated protein kinase by antigen receptor and Ca2+ in T lymphocytes. J Exp Med 203: 1665–1670.

4. Hormann S, Broucke G, Krause U, Pardel J, Vertommen D, et al. (2002) Activation of AMP-activated protein kinase leads to the phosphorylation of elongation factor 2 and an inhibition of protein synthesis. Curr Biol 12: 1419–1423.

5. Carling D, Zannit VA, Hardie DG (1987) A common binary protein kinase cascade inactivates the regulatory enzymes of fatty acid and cholesterol biosynthesis. FEBS Lett 223: 217–222.

6. Dowling RJ, Zakkhani M, Fantus IG, Pollak M, Sonenberg N (2007) Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 67: 10894–10812.

7. Sanchez-Cespedes M, Parrella P, Esteller M, Nonoto S, Trink B, et al. (2002) Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. Cancer Res 62: 3659–3662.

8. Xiang X, Saha AK, Wen R, Ruderman NB, Luo Z (2004) AMP-activated protein kinase activators can inhibit the growth of prostate cancer cells by multiple mechanisms. Biochem Biophys Res Commun 321: 161–167.

9. Evans JM, Donnelly LA, Ensmale-Smith AM, Alessi DR, Morris AD (2005) Metformin and reduced risk of cancer in diabetic patients. BMJ 330: 1304–1305.

10. Giardiello FM, Welsh SB, Hamilton SR, Offerhaus GJ, Gitterlaho AM, et al. (1987) Increased risk of cancer in the Peutz-Jeghers syndrome. N Engl J Med 316: 1511–1514.

11. Nakao M, Miyoshi H, Seldin MF, Imamura M, Oshima M, et al. (2002) Hepatocellular carcinoma caused by loss of heterozygosity in Lkb1 gene knockout mice. Cancer Res 62: 4549–4553.

12. Wang W, Guan KL (2009) AMP-activated protein kinase and cancer. Acta Physiol (Oxf) 196: 53–61.

13. Siegel AB, Zhu AX (2009) Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link. Cancer 115: 5651–5661.

14. Schütte K, Bornschein J, Malfertheiner P (2009) Hepatocellular carcinoma – epidemiological trends and risk factors. Dig Dis 27: 80–92.

15. Wood WJ, Rawlings J, Evans H, Lim CN (1988) Hepatocellular carcinoma: importance of histologic classification as a prognostic factor. Am J Surg 155: 653–656.

16. Ichida F, Tsoi T, Omata M, Ichida T, Inoue K, et al. (1996) New Inuyama classification; new criteria for histological assessment of chronic hepatitis. Int J Hepatol 1: 61–67.

17. Koomagi R, Volm M (1999) Expression of Fas (CD95/APO-1) and Fas ligand in lung cancer, its prognostic and predictive relevance. Int J Cancer 84: 239–243.

18. Garber K (2006) Energy deregulation: licensing tumors to grow. Science 312: 1158–1159.

19. Kahn BB, Alquier T, Carling D, Hardie DG (2005) AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab 1: 15–23.

20. Qu Z, Zhang Y, Liao M, Chen Y, Zhao J, et al. (2012) In vivo and in vitro antitumoral action of metformin on hepatocellular carcinoma. Hepatol Res 42: 920–923.

21. Chen HP, Shieh JJ, Chang CC, Chen TT, Lin JT, et al. (2013) Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies. Gut 62:606–15.

22. Shaw RJ (2006) Glucose metabolism and cancer. Curr Opin Cell Biol 18: 598–604.

23. Garber K (2006) Energy deregulation: licensing tumors to grow. Science 312: 1158–1159.

24. Kahn BB, Alquier T, Carling D, Hardie DG. (2005) AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab 1: 15–23.

25. Ludwig SJ, Shao AH, Haffner SM, Thompson TJ, Daviglus ML, et al. (2003) Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies. Gut 62:606–15.

26. Tietjen M, Ylikorkala A, Makela TP (1999) Growth suppression by Lkb1 is mediated by a G1 cell cycle arrest. Proc Natl Acad Sci U S A 96: 9248–9251.

27. Short JD, Dere R, Houston KD, Cai SL, Kim J, et al. (2010) AMPK-mediated phosphorylation of murine p27 at T197 promotes binding of 14-3-3 proteins and increases p27 stability. Mol Carcinog 49: 429–439.

28. Rattan R, Giri S, Singh AK, Singh I (2005) 5-Aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside inhibits cancer cell proliferation in vitro and in vivo via AMPK-activated protein kinase. J Biol Chem 280: 39582–39593.

29. Heazle N, Schumacher V, Menko FH, Olschwang S, Boardman LA, et al. (2006) Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. Clin Cancer Res 12: 3209–3215.

30. Tietjen M, Ylikorkala A, Makela TP (1999) Growth suppression by Lkb1 is mediated by a G1 cell cycle arrest. Proc Natl Acad Sci U S A 96: 9248–9251.

31. Xiang X, Saha AK, Wen R, Ruderman NB (2004) AMP-activated protein kinase activators can inhibit the growth of prostate cancer cells by multiple mechanisms. Biochem Biophys Res Commun 321: 161–167.

32. Nam M, Lee WH, Bae EJ, Kim SG (2008) Compound C inhibits clonal expansion of preadipocytes by increasing p21 level irrespectively of AMPK activation. J Cell Sci 121: 3579–3587.

33. Liang J, Shao AH, Haffner SM, Thompson TJ, Daviglus ML, et al. (2003) Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies. Gut 62:606–15.

34. Rahman MA, Dhar DK, Yamaguchi E, Maruyama S, Sato T, et al. (2001) Antitumoral action of metformin on hepatocellular carcinoma. Hepatol Res 42: 920–923.

35. Suzuki M, Ichihara M, Inoue K, et al. (1996) New Inuyama classification; new criteria for histological assessment of chronic hepatitis. Int J Hepatol 1: 61–67.